Park Ryan, Spritz Samantha, Zeng Anne Y, Erukulla Rohith, Zavala Deneb, Merchant Tasha, Gascon Andres, Jung Rebecca, Bigit Bianca, Azar Dimitri T, Chang Jin-Hong, Jalilian Elmira, Djalilian Ali R, Guaiquil Victor H, Rosenblatt Mark I
Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA.
Int J Mol Sci. 2025 May 13;26(10):4663. doi: 10.3390/ijms26104663.
Nociceptors respond to noxious stimuli and transmit pain signals to the central nervous system. In the cornea, the nociceptors located in the most external layer provide a myriad of sensation modalities. Damage to these corneal nerve fibers can induce neuropathic pain. In response, corneal nerves become sensitized to previously non-noxious stimuli. Assessing corneal pain origin is a complex ophthalmic challenge due to variations in its causes and manifestations. Current FDA-approved therapies for corneal nociceptive pain, such as acetaminophen and NSAIDs, provide only broad-acting relief with unwanted side effects, highlighting the need for precision medicine for corneal nociceptive pain. A few targeted treatments, including perfluorohexyloctane (F6H8) eye drops and Optive Plus (TRPV1 antagonist), are FDA-approved, while others are in preclinical development. Treatments that target signaling pathways related to neurotrophic factors, such as nerve growth factors and ion channels, such as the transient receptor potential (TRP) family or tropomyosin receptor kinase A, may provide a potential combinatory therapeutic approach. This review describes the roles of nociceptors in corneal pain. In addition, it evaluates molecules within nociceptor signaling pathways for their potential to serve as targets for efficient therapeutic strategies for corneal nociceptive pain aimed at modulating neurotrophic factors and nociceptive channel sensitivity.
伤害感受器对有害刺激做出反应,并将疼痛信号传递到中枢神经系统。在角膜中,位于最外层的伤害感受器提供多种感觉模式。这些角膜神经纤维受损会诱发神经性疼痛。作为反应,角膜神经会对先前无害的刺激变得敏感。由于角膜疼痛的原因和表现存在差异,评估其疼痛起源是一项复杂的眼科挑战。目前美国食品药品监督管理局(FDA)批准的用于治疗角膜伤害性疼痛的疗法,如对乙酰氨基酚和非甾体抗炎药,只能提供广泛的缓解且伴有不良副作用,这凸显了针对角膜伤害性疼痛的精准医学的必要性。一些靶向治疗方法,包括全氟己基辛烷(F6H8)滴眼液和Optive Plus(瞬时受体电位香草酸亚型1拮抗剂)已获FDA批准,而其他一些则正处于临床前开发阶段。针对与神经营养因子相关的信号通路(如神经生长因子)以及离子通道(如瞬时受体电位(TRP)家族或原肌球蛋白受体激酶A)的治疗方法,可能提供一种潜在的联合治疗途径。这篇综述描述了伤害感受器在角膜疼痛中的作用。此外,它还评估了伤害感受器信号通路中的分子,看它们有无潜力作为针对角膜伤害性疼痛的有效治疗策略的靶点,这些策略旨在调节神经营养因子和伤害性通道的敏感性。